DDInter364 DDInter518
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Chlorpropamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Metamfetamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metamfetamine
Metamfetamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Chlorpropamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexfenfluramine (Compound)
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Chlorpropamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Dexfenfluramine
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Chlorpropamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexfenfluramine (Compound)
Chlorpropamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine